ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes.

BACKGROUND Gains of a gene due to DNA polyploidy versus amplification of the specific locus are distinct molecular alterations in tumors. OBJECTIVE We quantified copy number gains of ALK gene due to unspecific polyploidy versus amplifications of the specific locus in a series of non-small cell lung cancers. METHODS The locus specific ALK copy (LSI) number status was evaluated in 205 cases by FISH. Ratio LSI ALK copy number corrected for control probes CEP2, CEP3 and CEP17 (CEPs) was scored. Amplification of the specific ALK locus was defined when ratio set to ≥ 2 while polyploidy was interpreted when the increase in gene copy resulted < 2 in ratio (LSI/control CEPs). RESULTS Twenty one cases (10.2%) showed ≥ 8 ALK signals, 68 cases (33.2%) 3-7 signals and 116 cases (56.6%) a mean of 2 signals. Only 2/21 cases of the cohort harboring ≥ 8 signals showed a ratio ≥ 2 after CEPs correction interpretable as amplified, showing numerous doubled fluorescent spots. All the remaining cases showed a mirrored number of fluorescent spots per each CEPs, interpretable as polyploidy. CONCLUSION We detected a high prevalence of ALK gene copy number usually due to polyploidy rather than ALK locus amplification, the latter visible prevalently as double minutes.

[1]  Eun Kyung Kim,et al.  ALK Gene Copy Number Gain and Immunohistochemical Expression Status Using Three Antibodies in Neuroblastoma , 2016, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[2]  W. Liang,et al.  Improving Selection Criteria for ALK Inhibitor Therapy in Non–Small Cell Lung Cancer: A Pooled-Data Analysis on Diagnostic Operating Characteristics of Immunohistochemistry , 2016, The American journal of surgical pathology.

[3]  A. Harding,et al.  Size Does Matter: Why Polyploid Tumor Cells are Critical Drug Targets in the War on Cancer , 2014, Front. Oncol..

[4]  W. Franklin,et al.  Native and rearranged ALK copy number and rearranged cell count in non–small cell lung cancer , 2013, Cancer.

[5]  W. Franklin,et al.  Diagnostic assays for identification of anaplastic lymphoma kinase‐positive non–small cell lung cancer , 2013, Cancer.

[6]  Tae Min Kim,et al.  Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  S. Knuutila,et al.  True 3q Chromosomal Amplification in Squamous Cell Lung Carcinoma by FISH and aCGH Molecular Analysis: Impact on Targeted Drugs , 2012, PloS one.

[8]  M. Varella‐Garcia,et al.  Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization–positive nonsmall cell lung cancer , 2012, Cancer.

[9]  U. Pastorino,et al.  Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene. , 2012, Lung cancer.

[10]  Tatiana G. Kutateladze,et al.  Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[11]  Yuan Yuan,et al.  Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP , 2011, Journal of hematology & oncology.

[12]  Ryohei Katayama,et al.  Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK , 2011, Proceedings of the National Academy of Sciences.

[13]  S. Serrano,et al.  Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[15]  Y. Shu,et al.  Multicolor fluorescence in situ hybridization and comparative genomic hybridization reveal molecular events in lung adenocarcinomas and squamous cell lung carcinomas. , 2008, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[16]  E. Gebhart.  Double minutes, cytogenetic equivalents of gene amplification, in human neoplasia—a review , 2005, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[17]  R. Margolis,et al.  Multiple centrosomes arise from tetraploidy checkpoint failure and mitotic centrosome clusters in p53 and RB pocket protein-compromised cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[18]  M. Tsao,et al.  Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization. , 2001, Cancer genetics and cytogenetics.

[19]  J. Winfield,et al.  Hydroxyurea accelerates the loss of epidermal growth factor receptor genes amplified as double-minute chromosomes in human glioblastoma multiforme. , 1996, Neurosurgery.

[20]  J. Testa,et al.  Detection of aneuploidy in interphase nuclei from non-small cell lung carcinomas by fluorescence in situ hybridization using chromosome-specific repetitive DNA probes. , 1996, Cancer genetics and cytogenetics.

[21]  D. V. Von Hoff,et al.  Evidence of gene amplification in the form of double minute chromosomes is frequently observed in lung cancer. , 1993, Cancer genetics and cytogenetics.

[22]  J. Siegfried,et al.  Chromosome abnormalities in human non-small cell lung cancer. , 1992, Cancer research.

[23]  A. Tulusan,et al.  Incidence of double minutes, cytogenetic equivalents of gene amplification, in human carcinoma cells , 1984, International journal of cancer.